中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
4期
350-352
,共3页
子宫内膜异位症%促性腺激素释放激素激动剂%避孕药
子宮內膜異位癥%促性腺激素釋放激素激動劑%避孕藥
자궁내막이위증%촉성선격소석방격소격동제%피잉약
Endometriosis%Gonadotropin-releasing hormone agonist%Contraceptives
目的 探讨在子宫内膜异位症中促性腺激素释放激素激动剂与口服避孕药联合的临床应用价值.方法 选取2012年1-12月在我院诊断为子宫内膜异位症患者186例,应用随机数字表分为对照组93例和观察组93例,对照组于腹腔镜手术保守治疗后给予妈富隆术后月经第1天口服,1片/d,连续6个月.观察组在手术保守治疗基础上给予以下药物治疗:诺雷德术后1周开始应用,3.6 mg皮下注射,每4周1次,连续3次;妈富隆于诺雷德用药结束后1片/d连续口服3个月,观察两组患者治疗前后总主观症状评分和治疗有效率、受孕率及不良反应发生情况.结果 观察组治疗后总主观症状评分为(0.91 ±0.32)分,明显低于对照组[(1.64±0.74)分],组间比较差异有统计学意义(t=8.73,P＜0.01);观察组治疗有效率为95.70％(89/93),明显高于对照组[82.80％(77/93)],组间比较差异有统计学意义(x2 =4.328,P＜0.05);观察组不良反应发生率为4.30％ (4/93),复发率为3.23％(3/93),均明显低于对照组[16.13％ (15/93)与10.75％ (10/93)],组间比较差异均具有统计学意义(x2值分别为4.854、5.168,P均＜0.05);观察组治疗后不孕患者受孕率为85.71％(12/14),明显高于对照组[61.54％(8/13)],组间比较差异有统计学意义(x2=3.987,P＜0.05).结论 促性腺激素释放激素激动剂联合避孕药能够明显缓解子宫内膜异位症患者临床症状,减少不良反应,降低复发率,提高临床治疗效果及不孕患者受孕率,值得推广应用.
目的 探討在子宮內膜異位癥中促性腺激素釋放激素激動劑與口服避孕藥聯閤的臨床應用價值.方法 選取2012年1-12月在我院診斷為子宮內膜異位癥患者186例,應用隨機數字錶分為對照組93例和觀察組93例,對照組于腹腔鏡手術保守治療後給予媽富隆術後月經第1天口服,1片/d,連續6箇月.觀察組在手術保守治療基礎上給予以下藥物治療:諾雷德術後1週開始應用,3.6 mg皮下註射,每4週1次,連續3次;媽富隆于諾雷德用藥結束後1片/d連續口服3箇月,觀察兩組患者治療前後總主觀癥狀評分和治療有效率、受孕率及不良反應髮生情況.結果 觀察組治療後總主觀癥狀評分為(0.91 ±0.32)分,明顯低于對照組[(1.64±0.74)分],組間比較差異有統計學意義(t=8.73,P＜0.01);觀察組治療有效率為95.70％(89/93),明顯高于對照組[82.80％(77/93)],組間比較差異有統計學意義(x2 =4.328,P＜0.05);觀察組不良反應髮生率為4.30％ (4/93),複髮率為3.23％(3/93),均明顯低于對照組[16.13％ (15/93)與10.75％ (10/93)],組間比較差異均具有統計學意義(x2值分彆為4.854、5.168,P均＜0.05);觀察組治療後不孕患者受孕率為85.71％(12/14),明顯高于對照組[61.54％(8/13)],組間比較差異有統計學意義(x2=3.987,P＜0.05).結論 促性腺激素釋放激素激動劑聯閤避孕藥能夠明顯緩解子宮內膜異位癥患者臨床癥狀,減少不良反應,降低複髮率,提高臨床治療效果及不孕患者受孕率,值得推廣應用.
목적 탐토재자궁내막이위증중촉성선격소석방격소격동제여구복피잉약연합적림상응용개치.방법 선취2012년1-12월재아원진단위자궁내막이위증환자186례,응용수궤수자표분위대조조93례화관찰조93례,대조조우복강경수술보수치료후급여마부륭술후월경제1천구복,1편/d,련속6개월.관찰조재수술보수치료기출상급여이하약물치료:낙뢰덕술후1주개시응용,3.6 mg피하주사,매4주1차,련속3차;마부륭우낙뢰덕용약결속후1편/d련속구복3개월,관찰량조환자치료전후총주관증상평분화치료유효솔、수잉솔급불량반응발생정황.결과 관찰조치료후총주관증상평분위(0.91 ±0.32)분,명현저우대조조[(1.64±0.74)분],조간비교차이유통계학의의(t=8.73,P＜0.01);관찰조치료유효솔위95.70％(89/93),명현고우대조조[82.80％(77/93)],조간비교차이유통계학의의(x2 =4.328,P＜0.05);관찰조불량반응발생솔위4.30％ (4/93),복발솔위3.23％(3/93),균명현저우대조조[16.13％ (15/93)여10.75％ (10/93)],조간비교차이균구유통계학의의(x2치분별위4.854、5.168,P균＜0.05);관찰조치료후불잉환자수잉솔위85.71％(12/14),명현고우대조조[61.54％(8/13)],조간비교차이유통계학의의(x2=3.987,P＜0.05).결론 촉성선격소석방격소격동제연합피잉약능구명현완해자궁내막이위증환자림상증상,감소불량반응,강저복발솔,제고림상치료효과급불잉환자수잉솔,치득추엄응용.
Objective To investigate the treatment effect of gonadotropin releasing hormone agonist and oral contraceptive on endometriosis diseases.Methods One hundred and eighty-six cases with endometriosis who were hospitalized in Traditional Chinese Medicine Hospital of Fangshan District of Beijing from Jan.2012 to Dec.2012,were randomly divided into control group (93 cases) and observation group (93 cases).Patients in control group were given Marvelon by oral from the first day of menstruation after operation to 6 months,1 tablet/day,and patients in observation group were given Marvelon combined with Zoladex after laparoscopic conservative treatment (3.6 ml subcutaneous injected Zoladex from the first week after operation,4 weeks/time,3 times).The total subjective symptom scores,efficacy rate,Pregnancy rate and adverse reaction were calculated and recorded.Results Subjective symptom score of observation group was (0.91 ± 0.32),significantly lower than that of the control group (1.64 ± 0.74 ; t =8.73,P ＜ 0.01).The efficiency rate in observation group were 95.70％ (89/93) was significantly higher than that in control group(82.80％ (77/93) ;t =4.328,P ＜0.05).Adverse reactions rate and reoccurrence in observation group were 4.30％ (4/93) and 3.23％ (3/93),lower than that of the control group(16.13％ (15/93) and 10.75％ (10/93) ; x2 =4.854,5.168 ; P ＜ 0.05).After treatment,the pregnancy rate in infertile patients of observation group the was 85.71％ (12/14),significantly higher than that of the control group (61.54％ (8/13),x2 =3.987,P ＜ 0.05).Conclusion Gonadotropinreleasing hormone agonist combined contraceptive is worthy of recommendation due to alleviating clinical symptoms,reducing adverse reactions occur,the relapse rate and improving the chances of conceiving infertility patients.
